Polyphenol supplementation did not affect insulin sensitivity and fat deposition during one-month overfeeding in randomized placebo-controlled trials in men and in women.
Segrestin B., Delage P., Nemeth A., Seyssel K., Disse E., Nazare J.-A., Lambert-Porcheron S., Meiller L., Sauvinet V., Chanon S., Simon C., Ratiney H., Beuf O., Pralong F., Yassin N.-a.-H., Boizot A., Gachet M., Pimentel K. J., Vidal H., Meugnier E., Vionnet N., Laville M.
Polyphenol supplementation did not affect insulin sensitivity and fat deposition during one-month overfeeding in randomized placebo-controlled trials in men and in women.
Two randomized placebo-controlled double-blind paralleled trials (42 men in Lyon, 19 women in Lausanne) were designed to test 2 g/day of a grape polyphenol extract during 31 days of high calorie-high fructose overfeeding. Hyperinsulinemic-euglycemic clamps and test meals with [1,1,1-13C3]-triolein were performed before and at the end of the intervention. Changes in body composition were assessed by dual-energy X-ray absorptiometry (DEXA). Fat volumes of the abdominal region and liver fat content were determined in men only, using 3D-magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) at 3T. Adipocyte's size was measured in subcutaneous fat biopsies. Bodyweight and fat mass increased during overfeeding, in men and in women. While whole body insulin sensitivity did not change, homeostasis model assessment of insulin resistance (HOMA-IR) and the hepatic insulin resistance index (HIR) increased during overfeeding. Liver fat increased in men. However, grape polyphenol supplementation did not modify the metabolic and anthropometric parameters or counteract the changes during overfeeding, neither in men nor in women. Polyphenol intake was associated with a reduction in adipocyte size in women femoral fat. Grape polyphenol supplementation did not counteract the moderated metabolic alterations induced by one month of high calorie-high fructose overfeeding in men and women. The clinical trials are registered under the numbers NCT02145780 and NCT02225457 at ClinicalTrials.gov and available at https://clinicaltrials.gov/ct2/show/NCT02145780 and https://clinicaltrials.gov/ct2/show/NCT02225457.
